BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)
The Pharma Data
DECEMBER 27, 2020
Currently, 16 potentially registration-enabling clinical trials are being conducted in China and globally, including 12 Phase 3 trials and four pivotal Phase 2 trials. Advise patients to use sun protection. QARZIBA ® ? BeiGene Management Update Conference Call and Webcast Information. About BRUKINSA ® (zanubrutinib).
52 
Let's personalize your content